Lung Cancer Informational Study (LCIS)
Cancer, Enhanced Care, Decision-Making
About this trial
This is an interventional supportive care trial for Cancer focused on measuring Cancer, Enhanced Care, Decision-Making, Advance Lung Cancer, Questionaires, Stage III Lung Cancer, Stage IV Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Pathologically or cytologically determined non-small cell lung cancer
- Stage IIIA, IIIB or IV extent
- No prior chemotherapy unless used in adjuvant therapy, completed more than two years ago, and no sign of any other malignancy active at this time
- Lung cancer-directed treatment with a standard or investigative chemotherapy regimen at entry
- Patients with brain metastasis are acceptable provided they are at least 3 weeks from completion of radiation therapy for brain metastasis, have stable and acceptable neurological status, and meet all other eligibility criteria. For patients undergoing gamma knife procedure, cognitive ability is the judgment call of the oncologist and study nurse as to whether comprehension is not a problem.
Exclusion Criteria:
- Performance status of KPS 60-100% or ECOG 0-2;
- No age limit
- Life expectancy greater than three months
- A caregiver (any family member or concerned other who consistently provides emotional and/or physical support) available to also participate
- Patient and caregiver are able to understand English (ability to repeat back in their own words)
Sites / Locations
- Memorial Sloan-Kettering Cancer Center
- University of Virginia- School of Nursing
Arms of the Study
Arm 1
Arm 2
Experimental
Other
1
2
Enhance Care (EC) will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits.
As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.